Evaluation of minimal residual disease using reverse-transcription polymerase chain reaction in t(8;21) acute myeloid leukemia:: A multicenter study of 51 patients

被引:64
作者
Morschhauser, F
Cayuela, JM
Martini, S
Baruchel, A
Rousselot, P
Socié, G
Berthou, P
Jouet, JP
Straetmans, N
Sigaux, F
Fenaux, P
Preudhomme, C
机构
[1] CHU Lille, Serv Malad Sang, F-59037 Lille, France
[2] CHU Lille, Lab Hematol A, F-59037 Lille, France
[3] INSERM, U524, F-59045 Lille, France
[4] INSERM, U462, Lab Hematol Mol, Paris, France
[5] Hop St Louis, Serv Hematol Pediat Hematol Clin Adulte & Greffe, Paris, France
[6] CHU Brest, Hematol Serv, F-29285 Brest, France
[7] Clin Univ St Luc, B-1200 Brussels, Belgium
关键词
D O I
10.1200/JCO.2000.18.4.788
中图分类号
R73 [肿瘤学];
学科分类号
100214 ;
摘要
Purpose: Most studies using various reverse transcription polymerase chain reaction (RT-PCR) techniques reported that the detection of the AML1-ETO fusion transcript was a common finding in long-term complete remission (CR) in acute myeloid leukemia (AML) with t(8;21) translocation, However, larger prospective studies with interlaboratory quality control may be important to investigate more precisely the clinical usefulness of studying minimal residual disease with RT-PCR in t(8;21) AML. Patients and Methods: We collected 223 marrow samples from 51 patients with t(8;21) AML diagnosed in five centers and tested all samples by two different RT-PCR techniques (a nested technique and a one-step technique, with a sensitivity of 10(-6) and 10(-5), respectively) in two different laboratories. Results: Samples from 14 patients in long persistent CR (median follow-up duration, 112 months) were taken at least twice, and all were PCR-negative by both techniques, Samples were prospectively taken from 37 patients after achievement of first CR and/or second CR, before intensive consolidation treatment, and every 3 to 6 months after completion of therapy. Patients who converted to PCR negativity with the one-step technique (60%) or both techniques (48%) after CR achievement had a longer CR duration than those with persistently positive PCR results (two-sided log-rank test, P = .0001), Patients who became PCR-negative with the one-step technique before intensive consolidation (23%) had a lower relapse rate (11% v 72%) and a longer CR duration than those who remained persistently PCR-positive at that point (two-sided log-rank test, P = .0015). Conclusion: Patients with AML with t(8;21) in longterm remission were all PCR-negative. In prospectively studied patients, a good correlation was found between negative PCR results and absence of relapse. Early negative results with the one-step RT-PCR technique, before consolidation treatment, seemed to carry an especially good prognosis, suggesting that RT-PCR analysis could help in choosing the type of consolidation therapy in patients with t(8;21) AML, (C) 2000 by American Society of Clinical Oncology.
引用
收藏
页码:788 / 794
页数:7
相关论文
共 25 条
[1]   Expression of the neural cell adhesion molecule CD56 is associated with short remission duration and survival in acute myeloid leukemia with t(8;21)(q22;q22) [J].
Baer, MR ;
Stewart, CC ;
Lawrence, D ;
Arthur, DC ;
Byrd, JC ;
Davey, FR ;
Schiffer, CA ;
Bloomfield, CD .
BLOOD, 1997, 90 (04) :1643-1648
[2]  
Burnett A. K., 1997, Blood, V90, p390A
[3]   Extramedullary leukemia adversely affects hematologic complete remission rate and overall survival in patients with t(8;21)(q22;q22): Results from cancer and leukemia group B 8461 [J].
Byrd, JC ;
Weiss, RB ;
Arthur, DC ;
Lawrence, D ;
Baer, MR ;
Davey, F ;
Trikha, ES ;
Carroll, AJ ;
Tantravahi, R ;
Qumsiyeh, M ;
Patil, SR ;
Moore, JO ;
Mayer, RJ ;
Schiffer, CA ;
Bloomfield, CD .
JOURNAL OF CLINICAL ONCOLOGY, 1997, 15 (02) :466-475
[4]  
Dieffenbach C.W., 1995, PCR PRIMER LAB MANUA
[5]  
Diverio D, 1998, BLOOD, V92, P784
[6]  
DOWNING JR, 1993, BLOOD, V81, P2860
[7]   Detection of AML1/ETO fusion transcripts in patients with t(8;21) acute myeloid leukemia after allogeneic bone marrow transplantation or peripheral blood progenitor cell transplantation [J].
Elmaagacli, AH ;
Beelen, DW ;
Stockova, J ;
Trzensky, S ;
Kroll, M ;
Schaefer, UW ;
Stein, C ;
Opalka, B .
BLOOD, 1997, 90 (08) :3230-3231
[8]   Persistence of the AML1/ETO fusion transcript in patients treated with allogeneic bone marrow transplantation for t(8;21) leukemia [J].
Jurlander, J ;
Caligiuri, MA ;
Ruutu, T ;
Baer, MR ;
Strout, MP ;
Oberkircher, AR ;
Hoffmann, L ;
Ball, ED ;
FreiLahr, DA ;
Christiansen, NP ;
Block, AW ;
Knuutila, S ;
Herzig, GP ;
Bloomfield, CD .
BLOOD, 1996, 88 (06) :2183-2191
[9]  
KOZU T, 1993, BLOOD, V82, P1270
[10]  
KUSEC R, 1994, LEUKEMIA, V8, P735